1-benzyl-4-(5-amino-pyridin-2-yl)-piperazine | 381706-46-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-benzyl-4-(5-amino-pyridin-2-yl)-piperazine
• 英文别名: 6-(4-Benzylpiperazin-1-yl)pyridin-3-amine
• CAS: 381706-46-3
• 化学式: C₁₆H₂₀N₄
• 分子量: 268.362
• InChiKey: OGVMVTQQAZPEGC-UHFFFAOYSA-N

物化性质

• 沸点：
  482.0±45.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  45.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  4'-Isopropyl-6-methyl-biphenyl-2-carboxylic acid 、 1-benzyl-4-(5-amino-pyridin-2-yl)-piperazine 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 4'-isopropyl-6-methyl-biphenyl-2-carboxylic acid [2-(4-benzyl-piperazin-1-yl)-pyridin-5-yl]-amide
  参考文献：
  名称：

  Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors

  摘要：

  本发明涉及一种化合物，其化学式为（I），其中A、U、V、X、Z、R1、Y、R2和R3在说明中有定义，或其生理上可接受的盐、溶剂或衍生物，以及制备所述化合物的组合物和方法，以及它们在治疗由apoB-100和/或MTP抑制剂改善的状况中的应用。

  公开号：

  US20040009988A1
• 作为产物：
  描述：

  1-benzyl-4-(5-nitro-pyridin-2-yl)-piperazine 在 tin(ll) chloride 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 1.5h， 生成 1-benzyl-4-(5-amino-pyridin-2-yl)-piperazine
  参考文献：
  名称：

  Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors

  摘要：

  本发明涉及一种化合物，其化学式为（I），其中A、U、V、X、Z、R1、Y、R2和R3在说明中有定义，或其生理上可接受的盐、溶剂或衍生物，以及制备所述化合物的组合物和方法，以及它们在治疗由apoB-100和/或MTP抑制剂改善的状况中的应用。

  公开号：

  US20040009988A1

文献信息

• BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS
  申请人：Dierks Christine

  公开号：US20100197659A1

  公开（公告）日：2010-08-05

  The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

  该发明提供了一种调节刺猬信号通路活性的方法。具体来说，该发明提供了一种抑制由于Ptc功能丧失、刺猬功能增强、smoothened功能增强或Gli功能增强等表型引起的异常生长状态的方法，包括将细胞与化合物I式的足够量接触。
• Benzamide derivatives and their use as apob-100 and mtp inhibitors
  申请人：——

  公开号：US20040024215A1

  公开（公告）日：2004-02-05

  The present invention relates to a compound of formula (I); wherein R 1 represents isopropyl or trifluoromethyl; R 2 represents hydrogen, C 1-4 alkyl, chloro, fluoro or trifluoromethyl; R 3 represents(i) phenyl, optionally substituted by cyano, halogen, trifluoromethyl or an optionally substituted 5-membered heteroaromatic group, where optional substitution is effected by C 1-4 alkyl, (ii) a 5-membered heteroaromatic group, optionally substituted by halogen, cyano or C 1-4 alkyl, (ii) aminocabonyl, or(iv) ethyl or eth-1-enyl; R 4 represents cyano, methyl, acetyl, a 5-membered heteoaromatic group, optionally substituted by C 1-4 alkyl or phenyl or a group X—Y-Z; X represents a carboxy, oxo, C 1-6 alkylene, carboxamido or thiocarboxamido linking group; Y represents a direct link or C 1-4 alkylene, Z represents (i) hydrogen, (ii) trifluoromethyl, (iii) cyano, (iv) phenyl (v) a 5- or 6-membered heteroaromatic group, optionally substituted by C 1-4 alkyl, with the proviso that when X represents C 1-4 alkylene, Y and Z do not represent a direct link and hydrogen respectively, or when X represents oxo, Y and Z do not represent C 1-6 alkylene and hydrogen respectively; or a physiologically acceptable salt, solvate or derivative thereof, to compositions comprising the compound, processes for their preparation and their use in treating conditions ameliorated by an apoB-100 and/or MTP inhibitor. 1

  本发明涉及一种具有如下结构的化合物（I）；其中R1代表异丙基或三氟甲基；R2代表氢、C1-4烷基、氯、氟或三氟甲基；R3代表（i）苯基，可选择由氰基、卤素、三氟甲基或可选择由C1-4烷基取代的5-成员杂芳基取代，（ii）一个可选择由卤素、氰基或C1-4烷基取代的5-成员杂芳基，（iii）氨基甲酰基，或（iv）乙基或乙-1-烯基；R4代表氰基、甲基、乙酰基、一个可选择由C1-4烷基或苯基取代的5-成员杂芳基，或一个X—Y-Z基团；X代表羧基、氧代、C1-6烷基、羧胺基或硫代羧胺基连接基团；Y代表直接键或C1-4烷基，Z代表（i）氢、（ii）三氟甲基、（iii）氰基、（iv）苯基、（v）一个可选择由C1-4烷基取代的5-或6-成员杂芳基，但有一个条件，即当X代表C1-4烷基时，Y和Z不分别代表直接键和氢，或当X代表氧代时，Y和Z不分别代表C1-6烷基和氢；或其生理上可接受的盐、溶剂合物或衍生物，以及包含该化合物的组合物、其制备方法及其在治疗由apoB-100和/或MTP抑制剂改善的疾病中的用途。
• COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS
  申请人：Gao Wenqi

  公开号：US20090203666A1

  公开（公告）日：2009-08-13

  The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of Formula I.

  本发明提供了一种调节刺猬信号通路活性的方法。具体而言，本发明提供了一种通过接触细胞与化合物I的足够量来抑制由于Ptc功能缺失、刺猬功能增强、平滑蛋白功能增强或Gli功能增强等表型引起的异常生长状态的方法。
• Smoothened antagonism for the treatment of hedgehog pathway-related disorders
  申请人：Novartis AG

  公开号：EP2617414A2

  公开（公告）日：2013-07-24

  The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch loss-of function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function by administering to a mammal combinations of Smoothened inhibitors (e.g., a compound of Formula I, Formula II, or Formula III, or any of the compounds listed herein or incorporated by reference) and Gli inhibitors, and/or Phosphatidylinositol 3-kinase (PI3K) inhibitors.

  本发明提供了调节（如拮抗）刺猬信号通路活性的方法，以及治疗刺猬相关疾病如癌症（如髓母细胞瘤）的方法。特别是，本发明提供了通过向哺乳动物施用 Smoothened 抑制剂（例如，式 I、式 II 或式 III 的化合物，或本文所列或通过参考文献并入的任何化合物）和 Gli 抑制剂和/或磷脂酰肌醇 3- 激酶（PI3K）抑制剂的组合，抑制表型（如 Ptch 功能缺失、刺猬蛋白功能增益、smoothened 功能增益或 Gli 功能增益）导致的异常生长状态的方法。
• SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS
  申请人：Novartis AG

  公开号：EP3023097A1

  公开（公告）日：2016-05-25

  The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function by administering to a mammal combinations of Smoothened inhibitors (e.g., a compound of Formula I, Formula II, or Formula III, or any of the compounds listed herein or incorporated by reference) and Gli inhibitors, and/or Phosphatidylinositol 3-kinase (PI3K) inhibitors.

  本发明提供了调节（如拮抗）刺猬信号通路活性的方法，以及治疗刺猬相关疾病如癌症（如髓母细胞瘤）的方法。特别是，本发明提供了通过向哺乳动物施用 Smoothened 抑制剂（例如，式 I、式 II 或式 III 的化合物，或本文所列或通过参考文献并入的任何化合物）和 Gli 抑制剂和/或磷脂酰肌醇 3- 激酶（PI3K）抑制剂的组合，抑制表型如 Ptch 功能缺失、Hedgehog 功能增益、smoothened 功能增益或 Gli 功能增益所导致的异常生长状态的方法。